| Cat.No. | Name | Information |
|---|---|---|
| M2106 | Azilsartan | Azilsartan (TAK-536) is an angiotensin II type 1 (AT1) receptor antagonist with IC50 of 2.6 nM. Azilsartan induces ROS formation and apoptosis in HepG2 cells. Azilsartan shows neuroprotective and anticancer activity. |
| M10146 | TRV-120027 TFA | TRV-120027 (also known as TRV027) is an angiotensin II receptor type 1 (AT1R) antagonist and engages ß-arrestins while blocking G-protein signaling. |
| M3507 | Valsartan | Valsartan is an angiotensin II receptor antagonist with IC50 of ranging from 39.5 to 116 μM. |
| M5731 | LCZ696 | LCZ696, consisting of Valsartan and Sacubitril in a 1:1 molar ratio, is a first-in-class dual-action angiotensin receptor-neprilysin inhibitor (ARNi,angiotensin receptor-neprilysin inhibitor) for the study of hypertension and heart failure. |
| M9079 | Angiotensin-(1-7) | Angiotensin (1-7) is a synthetic heptapeptide identical to endogenous angiotensin-(1-7), inhibits purified canine angiotensin converting enzyme (ACE) activity with an IC50 of 0.65 μM. |
| M9056 | Losartan | Losartan is an angiotensin II receptor antagonist, competing with the binding of angiotensin II to AT1 receptors with IC50 of 20 nM. |
| M8987 | EMA401 | EMA401 (also known as Olodanrigan and PD-126055) is a highly selective angiotensin AT2 antagonist. |
| M6025 | Tranilast | Tranilast is an antiallergic agent. |
| M3917 | PD 123319 | PD 123319 is a potent, selective AT2 angiotensin II receptor antagonist with IC50 of 34 nM. |
| M3790 | Tasosartan | Tasosartan is a selective, potent, orally active and long-acting nonpeptide Angiotensin II type 1 (AT1) receptor antagonist. |
| M3511 | Olmesartan Medoxomil | Olmesartan Medoxomil is a compound which is hydrolyzed to olmesartan that is a selective AT1 subtype angiotensin II receptor antagonist. |
| M3503 | Candesartan | Candesartan is an angiotensin II receptor antagonist with IC50 of 0.26 nM. |
| M3289 | Telmisartan | Telmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension. |
| M3275 | Irbesartan | Irbesartan (SR-47436, BMS-186295) is a highly potent and specific angiotensin II type 1 (AT1) receptor antagonist with IC50 of 1.3 nM. |
| M3265 | Olmesartan | Olmesartan is an angiotensin II receptor antagonist with an IC50 of 7.7 nM. |
| M2674 | Eprosartan Mesylate | Eprosartan is a nonpeptide angiotensin II receptor antagonist, [3H]-eprosartan binds to the AT1 receptor with KD of 0.83 nM in rat vascular smooth muscle cells. |
| M2258 | Losartan potassium | Losartan potassium is a selective non-peptide angiotensin AT1 receptor antagonist. |
| M2164 | PD 123319 ditrifluoroacetate | PD 123319 ditrifluoroacetate is a potent, selective, non-peptide angiotensin AT2 receptor antagonist. |
| M2105 | Azilsartan medoxomil | Azilsartan Medoxomil is an effective angiotensin II Type 1 (AT1) receptor antagonist that inhibits RAAS more than 10,000 times more selectively than AT2, and is used to study hypertension. |
| M54755 | TRV055 hydrochloride | TRV055 hydrochloride, a G-protein-biased agonist, is a Gq-biased ligand of the angiotensin II receptor type 1 (AT1R). TRV055 hydrochloride is efficacious in stimulating cellular Gq-mediated signaling. |
| M54356 | (Sar1, Ile4, 8)-Angiotensin II | (Sar1,Ile4,8)-Angiotensin II is a functionally selective angiotensin II type 1 receptor (AT1R) agonist. |
| M54243 | Alamandine | Alamandine, a member of the renin-angiotensin system (RAS), a vasoactive peptide, is an endogenous ligand of the G protein-coupled receptor MrgD. |
| M54202 | (Sar1)-Angiotensin II | (Sar1)-Angiotensin II, an analogue of Angiotensin II, is a specific agonist of angiotensin AT1 receptor. |
| M54149 | TRV-120027 | TRV120027, a β-arrestin-1-biased agonist of the angiotensin II receptor type 1 (AT1R), engages ß-arrestins while blocking G-protein signaling. |
| M54047 | Angiotensin II (5-8), human | Angiotensin II (5-8), human is an endogenous C-terminal fragment of the peptide vasoconstrictor angiotensin II. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
